Depression: all studies (page 56) - The Consciousness Library

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Translational Psychiatry January 23, 2026 Stevan Nikolin, Clara Massaneda-Tuneu, Louise Brettell et al. 1 citation

Comparing treatments for severe and medication-resistant depression is essential for guiding clinical decision-making. In this meta-analysis, we investigate the efficacy of electroconvulsive therapy (ECT) compared to ketamine for the treatment of major depressive disorder (MDD) and address the discrepant results of prior meta-analyses. We systematically searched PubMED (MEDLINE), Embase, and...

DOI: 10.1038/s41398-026-03806-z Full text

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

DOI: 10.1016/j.jad.2026.121230 Full text Anxiety Treatment-resistant depression Iv ketamine Real-world evidence +1

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

Journal of Neuroinflammation January 22, 2026 Ang Liu, Xiao-Qi Zhang, Jia-Xin Guo et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors,...

DOI: 10.1186/s12974-026-03699-1 Full text Depression Esketamine Animals Rats, sprague-dawley +8

Progress, potential and pitfalls of ketamine as a treatment for depression

Expert Opinion on Pharmacotherapy January 22, 2026 Diana Orsini, Sara Di Luch, Gabrielle F. M. Lovell et al.

Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clinical trials and real-world effectiveness studies supporting antidepressant effects. Larger studies have provided reassuring data supporting an adequate safety profile, including safety data with long-term treatment. Alternative routes of...

DOI: 10.1080/14656566.2026.2637587 Ketamine Treatment-resistant depression Antidepressant Clinical trial +4

Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment.

Neuroscience January 22, 2026 Guilherme Lodetti, Gislaine Zilli Réus, Eduardo Pacheco Rico

Pharmacotherapy for MDD is commonly prescribed to patients, yet fewer than half achieve remission. Moreover, many patients exhibit intolerant responses to pharmacological treatment, highlighting the need to explore new forms of therapy. The present work provides a narrative review of classic psychedelics as an alternative to MDD treatment. In addition, mechanisms by which psychedelics exert...

DOI: 10.1016/j.neuroscience.2026.01.022 Full text Major depressive disorder Neuroplasticity Classic psychedelics Treatment

Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.

Indian Journal of Psychological Medicine January 22, 2026 Zaid Ahmad Wani, Rajnish Raj, Shabir Ahmad Dar et al.

Depression is a significant global health issue, often accompanied by suicidality, which requires urgent and effective interventions. Oral ketamine is emerging as a potential rapid-acting treatment, but data on its efficacy and tolerability remain limited, particularly in the Indian context. Thus, this retrospective study was conducted to assess the response to oral ketamine in patients with...

DOI: 10.1177/02537176251415001 Full text Depression Oral ketamine Rapid-acting antidepressant Sociocultural factors +1

The Effects of a Brief Mindful Walking Intervention on Mindfulness, Depression, Anxiety and Stress in Novice Meditators

Appalachian State University January 21, 2026

Research suggests that regular mindfulness meditation practice leads to a variety of beneficial outcomes, including improved mood and well-being. Although mindfulness meditation has traditionally been practiced in various forms, the vast majority of the psychological literature on the topic has examined the effects of seated mindfulness exercises. Mindful walking has been practiced for...

DOI: 10.71889/5fylantbak.31070827

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

DOI: 10.1186/s12991-025-00626-1 Full text Esketamine Treatment-resistant depression Antidepressant therapies Gcc mental health +2

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

DOI: 10.1016/j.jad.2026.121208 Full text Esketamine Mdd Treatment-resistant depression Intranasal racemic ketamine +1

Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.

The Journal of Clinical Psychiatry January 21, 2026 Matheus G Marques, Aysegul Özerdem, Simon Kung et al. 1 citation

Objective: Treatment-resistant depression (TRD) affects one-third of patients with major depressive disorder, leading to increased morbidity, health care costs, and suicide risk. TRD lacks a standardized definition, complicating treatment selection. Current guidelines often group treatments broadly without clear prioritization, and evidence gaps persist, particularly regarding newer...

DOI: 10.4088/JCP.25cs16066 Full text